DEFA14A: Vaxart to Host Fireside Chat on Reverse Stock Split

Vaxart, Inc. announced a virtual fireside chat to discuss its reverse stock split proposal, which has received support from ISS and Glass Lewis, aimed at regaining Nasdaq compliance.

Summary

• Vaxart, Inc. will host a virtual stockholder fireside chat on Wednesday, August 20, 2025, at 4:30 p.m. ET / 1:30 p.m. PT.
• The chat will focus on the rationale for a reverse stock split and the need to regain Nasdaq compliance.
• Leading independent proxy advisory firms, Institutional Shareholder Services (ISS) and Glass Lewis, recommend stockholders support the reverse stock split proposal.
• Stockholders of record on July 29, 2025, are encouraged to vote by 11:59 p.m. Eastern Time on September 4, 2025.
• The company is a clinical-stage biotechnology firm developing oral recombinant pill vaccines for indications like coronavirus, norovirus, influenza, and HPV.

Sentiment

Score: 4

Explanation: The need for a reverse stock split to regain Nasdaq compliance is a significant negative indicator, reflecting past stock underperformance. However, the proactive communication and support from proxy advisory firms for the proposed solution provide a degree of stability and an expected path forward, preventing a lower score.

Positives

• Leading independent proxy advisory firms, ISS and Glass Lewis, recommend stockholders support the reverse stock split proposal, indicating external validation for the strategic move.
• Management is proactively engaging with stockholders through a fireside chat to address concerns and provide transparency regarding the reverse stock split and Nasdaq compliance.
• The company's proprietary oral recombinant pill vaccine delivery platform offers potential advantages such as no refrigeration required and elimination of needle-stick injury risk.

Negatives

• The company's stock price performance necessitates a reverse stock split to regain compliance with Nasdaq listing requirements, indicating a prior period of underperformance or low valuation.
• The need for a reverse stock split often signals underlying challenges with market perception or financial health that led to the non-compliance.

Risks

• Failure to secure stockholder approval for the reverse stock split could prevent the company from regaining Nasdaq compliance.
• Even with a reverse stock split, there is no guarantee that the company will maintain Nasdaq compliance long-term or that its stock price will appreciate.
• The company operates as a clinical-stage biotechnology firm, meaning its success is dependent on the successful development and commercialization of its vaccine candidates, which is inherently risky.

Future Outlook

The company aims to regain Nasdaq compliance through the proposed reverse stock split and plans to engage directly with stockholders to explain the rationale and address questions. Continued development of its oral vaccine pipeline for various indications is also implied.

Management Comments

• "Our leadership team is excited for this opportunity to connect with our stockholders directly."
• "This fireside chat is a chance for us to answer many of the frequently asked questions from our stockholders, particularly around the rationale for a reverse stock split and the need to regain Nasdaq compliance." Steven Lo, Chief Executive Officer of Vaxart.

Industry Context

Vaxart operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, specifically focusing on novel oral vaccine delivery platforms. The need for a reverse stock split to maintain Nasdaq listing is a common challenge for smaller biotech companies whose stock prices may fluctuate significantly due to clinical trial results, funding needs, or market sentiment, contrasting with larger, more established pharmaceutical companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the proposed reverse stock split, which will reduce the number of outstanding shares and increase the per-share price. The fireside chat offers an opportunity for direct engagement and clarification.
• Employees: Maintaining Nasdaq listing can provide stability and potentially better access to capital, which could indirectly benefit employees through continued operations and potential growth.
• Investors (potential): Regaining Nasdaq compliance could make the stock more attractive to institutional investors who have minimum price requirements or prefer exchange-listed securities.

Next Steps

• Host a virtual stockholder fireside chat on August 20, 2025.
• Collect stockholder votes on the reverse stock split proposal by September 4, 2025.
• Continue developing oral recombinant pill vaccines for coronavirus, norovirus, influenza, and HPV.

Key Dates

Recommendation

The proposed reverse stock split is a necessary step to regain Nasdaq compliance, which is crucial for maintaining investor confidence and market access. While the need for such a measure often signals underlying challenges, the support from ISS and Glass Lewis, coupled with management's proactive communication, suggests a structured approach to address the issue. However, a reverse split itself does not fundamentally change the company's operational performance or long-term prospects. Investors should hold to observe the outcome of the vote, the successful regaining of compliance, and future developments in the company's clinical pipeline before making further investment decisions. The underlying business (clinical-stage biotech) remains high-risk.

Keywords

Vaxart, VXRT, biotechnology, oral vaccines, reverse stock split, Nasdaq compliance, clinical-stage, ISS, Glass Lewis, proxy vote, fireside chat, vaccine development